THE WORLD'S LEADING OPTHALMIC GENE THERAPY TECHNOLOGY

Prof. Bin Li (the founder of Neurophth) initiated gene therapy studies for Leber’s hereditary optic neuropathy (LHON) in 2008

IIT clinical data with the longest follow-up time and the largest sample size for LHON gene therapy has been accumulated since 2011

BUILDING A BRIGHTER FUTURE FOR PATIENTS 

Becoming a World Leading Company in Ocular Gene Therapy

  • 2016
    Neurophth found
    in Wuhan, China
  • 10+
    Ophthalmic gene therapy
    drug candidates
  • 168

    Subjects treated in

    IIT studies initiated

    by Prof. Bin Li

  • 4Centres
    China
    (Wuhan,Suzhou,Shanghai)
    + U.S.
News Center
上一页
下一页